Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2026 04:00 ET | Source: Microbiotica

Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis

The study which compared MB310, a precision microbiome medicine, with placebo in 29 ulcerative colitis (UC) patients met its primary and secondary objectives to demonstrate safety, efficacy and...
September 17, 2025 04:00 ET | Source: Microbiotica

Microbiotica Announces Completion of Recruitment in its International Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma

CAMBRIDGE, United Kingdom, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
August 04, 2025 04:00 ET | Source: Microbiotica

Microbiotica Announces Completion of Recruitment in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients

CAMBRIDGE, United Kingdom, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
May 06, 2025 04:00 ET | Source: Microbiotica

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier

CAMBRIDGE, United Kingdom, May 06, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma Company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
April 29, 2025 04:00 ET | Source: Microbiotica

Microbiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma

CAMBRIDGE, United Kingdom, April 29, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
February 26, 2025 04:00 ET | Source: Microbiotica

Microbiotica presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma

CAMBRIDGE, United Kingdom, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
February 21, 2025 07:00 ET | Source: Microbiotica

Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis

CAMBRIDGE, United Kingdom, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
November 13, 2024 04:00 ET | Source: Microbiotica

Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients

CAMBRIDGE, United Kingdom, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
October 07, 2024 04:00 ET | Source: Microbiotica

Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma

CAMBRIDGE, United Kingdom, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic...
August 27, 2024 04:00 ET | Source: Microbiotica

Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies

CAMBRIDGE, United Kingdom, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products...